OCREVUS IS NOW AVAILABLE IN 2 ROUTE-OF-ADMINISTRATION OPTIONS
No matter which route of administration your patients have been prescribed—OCREVUS® [IV] or OCREVUS ZUNOVO, the subcutaneous formulation—you can expect the same industry-recognized* support and tools to help patients access their medicine, including:
Access and reimbursement support to help meet the needs of patients and practices throughout the treatment journey after OCREVUS or OCREVUS ZUNOVO is prescribed
Resources for practices
Dosing and Administration Guide
The same financial support to help eligible patients afford their medicine regardless of insurance type—including co-pay assistance for eligible commercially insured patients†
Access and Reimbursement Guide
Visit us at Booth 24 to see a demonstration of OCREVUS ZUNOVO administration or scan the QR code to get in touch with a Genentech representative.
HCP=health care professional; IV=intravenous.
*Genentech achieved “best-in-class” status in patient support for neurology in 2023 according to the Nuvera Life Sciences Patient services Utilization, Recognition and Experience (PURE) Report.
†Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.
OCREVUS® and its logo are registered trademarks and OCREVUS ZUNOVO™ and its logo are trademarks of Genentech, Inc.
©2024 Genentech USA, Inc. So. San Francisco, CA All rights reserved.
M-US-00025005(v1.0) 09/24
MEETING TIPS
Quick Links
For handy access to most of the links mentioned below and to download your certificate of attendance, visit AAN.com/FCQuickLinks.
WiFi
WiFi is available throughout the conference.
Network: Caesars_Resorts
AAN Conferences Mobile App and Online Platform
Download the AAN Conferences mobile app for the most accurate, up-tothe-minute information. Enjoy a seamless experience between the mobile app and online platform, which also allow you to revisit past sessions.
Conference attendees have access to content through November 11, 2024. Visit AAN.com/FCOnline and use your 6-digit ID and password to log in to the online platform or view content on the AAN Conferences mobile app. It may take up to 48 hours after session completion for content to become available.
Have a Question?
Get your question answered by a speaker in real time. Join the discussion by logging into the AAN Conferences mobile app or online platform and navigating to the session you’d like to participate in. Select the ‘Q&A’ button at the top of the page and join the discussion!
Program Slides
Slides are available online at AAN.com/Materials or through the online platform or AAN Conferences mobile app. You can access program materials through August 1, 2025. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)
MEETING TIPS
Claiming CME Credits
Complete your evaluations to get your CME credits by November 11, 2024 (or August 1, 2025, with Fall Conference On Demand or APP On Demand) by using the AAN Conferences mobile app or by visiting AAN.com/CME. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker
Lactation and Prayer Rooms
Private rooms for nursing, pumping, and/or praying are available for use during the conference. Visit Registration for access.
Meals and Coffee Breaks
A light breakfast will be provided daily 30 minutes before the start of the first course. Lunch and coffee break times and locations are noted in the schedule.
Want More Time to Review Programs?
Add Fall Conference On Demand to your registration to extend your access to session recordings through August 1, 2025, at up to 55% savings. Check the back of your badge to see if you already have Fall Conference On Demand. If not, head to Registration or email aanfcsupport@cmrus.com by November 11, 2024, to purchase at the discounted rate.
Meeting Policies
Complete meeting policies are posted at AAN.com/ConfGuidelines
SCAN ME
MEETING TIPS
ACCME Accreditation
The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation
The American Academy of Neurology Institute (AANI), a subsidiary of the AAN, designates this live activity for a maximum of (42) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPN Statement
The American Board of Psychiatry and Neurology has reviewed the 2024 AAN Fall Conference and has approved the program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.
Exhibit Hall
Attend the Exhibit Hall Reception on Friday to network with colleagues and make new connections!
Learn about the latest advancements in products and services enhancing the lives of neurology patients and their care providers.
Complete your exhibit hall passport by visiting the participating booths and be entered into a drawing to win prizes, including a 2025 Annual Meeting registration.
MEETING-AT-A-GLANCE
THURSDAY, OCTOBER 24
Location: Octavius 9-11
Advanced Practice Provider Pre-conference (separate registration required)
FRIDAY, OCTOBER 25
Octavius 9-11
Octavius 19-21
Octavius 15-16
Octavius 17-18
Opening Keynote: Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD) Octavius 9-11
Neurology Update 1: Multiple Sclerosis; Headache
Neurology Update 2: Sleep; Brain Death
Neuromuscular Junction Disorders: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Practice Management 1: From Chatroom to Care Continuum: Elevating Patient Engagement Beyond Visits
Exhibit Hall Lunch
Anti-amyloid Therapy Update
Practice Management 2: Beyond the Basics: Optimizing the Onboarding Experience for New APPs
Leadership University 1: Knowing and Communicating Your Value
Neurology Update 3: Dementia; Cerebrovascular Disease
Controversies in Neurology
Practice Management 3: New Frontiers in Care: Exploring Innovative Service Lines for Community Practices
Exhibit Hall Reception Sponsored by Catalyst Pharmaceuticals
Leadership University 2: Leading from Where You Are: How to Advocate for Change at Any Level
Leadership University 3: Emotional Intelligence in Action: Navigating Conflict in Difficult Times
SATURDAY, OCTOBER 26
Octavius 9-11
Neurology Update 4: Movement Disorders; Autonomic Disorders
Neurological Debate: Should Patients with a Single Unprovoked Seizure be Evaluated and Treated as if They Have Epilepsy?
Octavius 19-21
Octavius 15-16
Practice Management 4: From Payers to Partners: Strategies to Reduce Burden and Build Collaboration
Octavius 17-18
Neurology Update 5: Neuroimmunology and Infectious Disease; Neurohospitalist
Chronic Inflammatory Demyelinating Polyneuropathy
Neurology Update 6: Functional Neurology; Neurology in Vulnerable Populations
Neurology Education: Teaching on the Go: Effective Strategies for Busy Neurology Providers
Practice Management 5: Don’t Leave Money on the Table: Optimize Inpatient Coding with Refresher and Novel Codes
Clinical Trials Update
SUNDAY, OCTOBER 27
Octavius 9-11
Neurology Update 7: Neuromuscular Disease; Epilepsy
Practice Management 7: AI on Monday Mornings: Practical Applications for Busy MDs and BAs
Practice Management 6: Beyond the Bedside: Bite-sized Strategies for Value-based Care Success Skills Workshop: Neurological Examination Skills for Advanced Practice Providers
Octavius 19-21
Neuromyelitis Optica Spectrum Disorders Neuro-rheumatology
Neurology Update 8: Neuro-oncology; Neuro-opthalmology
Trigeminal Neuralgia: Mimics, Pharmacotherapy, and Surgical/Interventional Treatment
Exhibit Hall Break
Exhibit Hall Lunch
THURSDAY, OCTOBER 24
8:00 a.m.–5:00 p.m.
APP : AAN Advanced Practice
Provider Neurology Conference 7.5
Location: Octavius 9-11
Learning Objectives: This full day of education programming designed especially for advanced practice provider care team members dives deep into topics ranging from neurology fundamentals to clinical case studies in movement disorders, dizziness/vertigo, and radiculopathy and spinal stenosis. Programming will also touch on the hot topic of artificial intelligence and its impact on clinical documentation. Attendance at the APP Pre-conference is open only to those attending the 2024 AAN Fall Conference. Separate registration required.
Lecture/Faculty:
8:00 a.m.–8:05 a.m.
» Welcome and Introductions
Calli L. Cook, DNP, FNP-C, P, Atlanta, GA
Ryan Hakimi, DO, FAAN, Greenville, SC
8:05 a.m.–9:05 a.m.
» Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 1: Neuroanatomy Basics and Localizing the Lesion
Jaffar Khan, MD, FAAN, Atlanta, GA
9:05 a.m.–9:15 a.m.
» Break
9:15 a.m.–10:15 a.m.
» Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 2: Applied Neuroanatomy: Clinical Correlation
Jaffar Khan, MD, FAAN, Atlanta, GA
10:15 a.m.–10:25 a.m.
» Break
10:25 a.m.–11:10 a.m.
» Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging Techniques in Clinical Practice: Brain
Ryan Hakimi, DO, FAAN, Greenville, SC
11:10 a.m.–12:00 p.m.
» Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging Techniques in Clinical Practice: Spine
Ryan Hakimi, DO, FAAN, Greenville, SC
12:00 p.m.–1:00 p.m.
» Lunch/Networking 1:00 p.m.–2:00 p.m.
» Movement Disorders
Shannon Anderson, PA, Portland, OR
2:00 p.m.–3:00 p.m.
» Approach to Dizziness and Vertigo
Scott D. Eggers, MD, Rochester, MN
3:00 p.m.–3:15 p.m.
» Break
3:15 p.m.–4:15 p.m.
» Radiculopathy and Spinal Stenosis
Margaret Naclerio, PA, Boston, MA
4:15 p.m.–4:55 p.m.
» Clinical Documentation in Artificial Intelligence
Lidia Maria V. Moura, MD, PhD, MPH, FAAN, Boston, MA
4:55 p.m.–5:00 p.m.
» Wrap Up and Adjourn
Calli L. Cook, DNP, FNP-C, P, Atlanta, GA
Ryan Hakimi, DO, FAAN, Greenville, SC
SCHEDULE
8:00 a.m.–9:00 a.m.
C1: Opening Keynote: Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)
Location: Octavius 9-11
Learning Objectives: This keynote session will highlight the hallmark clinical and MRI features of MOG antibody-associated disease (MOGAD) and summarize its 2023 diagnostic criteria, offer guidance on when to order and how to interpret MOG-antibody test results, and review the current treatment approach and clinical trials available.
Lecture/Faculty:
8:00 a.m.–9:00 a.m.
» Myelin Oligodendrocyte Glycoprotein Antibody Disorders (MOGAD)
Eoin P. Flanagan, MBBCh, FAAN, Rochester, MN
9:00 a.m.–9:30 a.m.
Break
Location: Octavius Foyer
9:30 a.m.–11:00 a.m.
C2 : Neurology Update 1: Multiple Sclerosis; Headache 1.5
Location: Octavius 9-11
Learning Objectives: Multiple Sclerosis: Participants should understand the role of the optic nerve in MS diagnostic criteria, choose between different B-cell therapies in MS treatment, discuss the latest developments on BTK inhibitors in MS, analyze the role of Epstein-Barr Virus (EBV) in multiple sclerosis and potential treatment, review the current state of remyelinating therapies in MS, and explore Emerging MS Treatments on the Horizon.
Headache: Participants should improve the diagnosis and management of headache disorders across populations; become familiar with latest advances in migraine therapeutics; and evaluate recent positions statements, guidelines, and recommendations for clinical practice.
Lecture/Faculty:
9:30 a.m.–10:15 a.m.
» Multiple Sclerosis
Kristin M. Galetta, MD, Palo Alto, CA 10:15 a.m.–11:00 a.m.
» 2024 Headache Update
Teshamae Monteith, MD, FAAN, Miami, FL
FRIDAY, OCTOBER 25
9:30 a.m.–11:00 a.m.
C3 : Neuromuscular Junction Disorders: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Location: Octavius 19-21
This program is supported in part by educational grants from UCB, Inc. and argenx US Inc.
Learning Objectives: Participants should understand current methods of diagnosis of myasthenia gravis and be able to assess traditional and newer therapies used in myasthenia gravis.
Lecture/Faculty:
9:30 a.m.–9:55 a.m.
» Acetylcholine Receptor Antibody Positive Myasthenia Gravis
Min Kang, MD, San Francisco, CA
9:55 a.m.–10:15 a.m.
» Ocular and MuSK Myasthenia Gravis
Kathie Lin, MD, Palo Alto, CA
10:15 a.m.–10:35 a.m.
» Targeted Therapy in MG: Complement and FcRn Inhibition
Neelam Goyal, MD, Palo Alto, CA
10:35 a.m.–10:50 a.m.
» Challenging Cases from Clinical Practice
Neelam Goyal, MD, Palo Alto, CA
Kathie Lin, MD, Palo Alto, CA
Min Kang, MD, San Francisco, CA 10:50 a.m.–11:00 a.m.
» Questions and Answers
Neelam Goyal, MD, Palo Alto, CA
Kathie Lin, MD, Palo Alto, CA
Min Kang, MD, San Francisco, CA
Information is accurate as of October 1, 2024, and is subject to change.
FRIDAY, OCTOBER 25
9:30 a.m.–11:00 a.m.
C4 : Practice Management 1: From Chatroom to Care Continuum: Elevating Patient Engagement Beyond Visits 1.5
Location: Octavius 15-16
Learning Objectives: Participants should be able to employ a strategy for managing asynchronous patient communications, assess AI tools for use in managing patient messages, examine unique aspects of neurological care and patient communications, and consider use of novel care codes for revenue capture in non-face-to-face work.
Lecture/Faculty:
9:30 a.m.–10:15 a.m.
» From Chatroom to Care Continuum: Elevating Patient Engagement Beyond Visits
Brad C. Klein, MD, MBA, FAAN, Abington, PA 10:15 a.m.–11:00 a.m.
» From Chatroom to Care Continuum: Elevating Patient Engagement Beyond Visits
Carolyn M. Chamberlain, CMPE, Asheville, NC
9:30 a.m.–11:00 a.m.
L1: Knowing and Communicating Your Value 1.5
Location: Octavius 17-18
Learning Objectives: Leadership University sessions are open to all Fall Conference attendees and are designed to be inclusive of advanced practice providers, business administrators, trainees, and neurologists at all career stages. Participants should be able to improve their understanding of metrics that influence neurology professional’s monetary value (i.e., compensation), build awareness of data sources to benchmark compensation, and gain strategies for self-advocacy and self-promotion. Leadership development is personal development, so please join us!
Lecture/Faculty:
9:30 a.m.–11:00 a.m.
» Knowing and Communicating Your Value
David A. Evans, MBA, Dallas, TX
Pearce Korb, MD, FAAN, Richmond, VA
SCHEDULE
11:00 a.m.–1:00 p.m.
Exhibit Hall Lunch
Location: Exhibit Hall - Octavius 12
12:00 p.m.–12:45 p.m.
APP Networking Session
Location: Octavius 15-16
1:00 p.m.–2:30 p.m.
C5 : Neurology Update 2: Sleep; Brain Death 1.5
Location: Octavius 9-11
Learning Objectives: Sleep: Participants should be able to streamline the diagnostic process for restless legs syndrome (RLS), obstructive sleep apnea (OSA), and insomnia by using the most current diagnostic criteria and efficient screening tools, and integrate recent guideline updates to reduce diagnostic complexity and enhance accuracy in clinical practice; be able to identify and critically evaluate at least two emerging treatment options for RLS, OSA, and Insomnia, and develop personalized, evidence-based treatment plans that incorporate updated therapies and reorganized treatment pathways; and learn to dispel common myths and misconceptions surrounding these disorders, improving patient education and adherence to care plans.
Brain Death: Participants will review the 2023 AAN/AAP/CNS/SCCM guidelines for determination of brain death/death by neurologic criteria and examine legal controversies related to determination of brain death/death by neurological criteria in the context of current statutes on determination of death.
Lecture/Faculty: 1:00 p.m.–1:45 p.m.
» Neurology Meets Sleep: Streamlining Diagnoses and Revamping Treatments for RLS, OSA, and Insomnia
Rachel Marie E. Salas, MD, MEd, FAAN, Columbia, MD 1:45 p.m.–2:30 p.m.
» Brain Death
Ariane Lewis, MD, FAAN, New York, NY
SCHEDULE
1:00 p.m.–2:30 p.m.
C6 : Anti-amyloid Therapy Update
Location: Octavius 19-21
1.5
Learning Objectives: Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer’s disease; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and understand common scenarios in evaluating eligibility for anti-amyloid therapy.
Lecture/Faculty:
1:00 p.m.–1:30 p.m.
» Overview of Trials and Updates
Parichita Choudhury, MD, Sun City, AZ
1:30 p.m.–2:00 p.m.
» ARIA
Petrice M. Cogswell, MD, PhD, Rochester, MN
2:00 p.m.–2:30 p.m.
» Lessons Learned from One Year of Availability and Cases
Jonathan Graff-Radford, MD, FAAN, Rochester, MN
Petrice M. Cogswell, MD, PhD, Rochester, MN
FRIDAY, OCTOBER 25
1:00 p.m.–2:30 p.m.
C7: Practice Management 2: Beyond the Basics: Optimizing the Onboarding Experience for New APPs
Location: Octavius 15-16
1.5
Learning Objectives: Participants should be able to appraise their current APP onboarding procedures, evaluate the common and specific needs of their new hires, plan APP onboarding for their practices based on sound principles, and anticipate barriers to successful onboarding and reduce turnover.
Lecture/Faculty:
1:00 p.m.–1:45 p.m.
» Beyond the Basics: Optimizing the Onboarding Experience for New APPs
Louis A. Tramontozzi III, MD, Beverly, MA
1:45 p.m.–2:30 p.m.
» Beyond the Basics: Optimizing the Onboarding Experience for New APPs
Shannon Anderson, PA, Portland, OR
Parkinson’s care is demanding. The Parkinson’s Foundation is here to help.
Free resources to help you and your patients navigate Parkinson’s disease (PD). To learn more, visit Parkinson.org/Provider.
Helpline
Answers to PD questions and referrals to local resources. Staffed by health professionals. 1.800.4PD.INFO (473.4636). English and Español. Open M-F.
Patient and Family Education
Books, fact sheets, webinars, and in-person events to educate, engage and inspire.
Genetics Research Study
Genetic testing and counseling at no cost for patients with a PD diagnosis.
Professional Education (CME/CEU) Accredited, online courses on a variety of PD care topics.
“As clinicians, we never have as much time as we’d like with our patients. The Helpline is a great tool for patients to use between visits for lingering questions or for help finding the right resource.”
– Gavin Brown, MD, Community Neurologist
Information is accurate as of October 1, 2024, and is subject to change.
FRIDAY, OCTOBER 25
1:00 p.m.–2:30 p.m.
L2 : Leading from Where You Are: How to Advocate for Change at Any Level 1.5
Location: Octavius 17-18
Learning Objectives: Leadership University sessions are open to all Fall Conference attendees and are designed to be inclusive of advanced practice providers, business administrators, trainees, and neurologists at all career stages. Participants should be able to understand the role of the team and how to engage members, consider the use of high-functioning team models and assess outcomes, describe the importance of forecasting and strategically planning for leadership, and analyze the role of positivity and critical thinking when leading. Leadership development is personal development, so please join us!
Lecture/Faculty:
1:00 p.m.–2:30 p.m.
» How to Lead When You Aren’t the Leader
Lucretia Long, DNP, APRN-CNP, FAES, Columbus, OH
Calli L. Cook, DNP, APRN, FNP-C, FAANP, FAAN, Atlanta, GA
2:30 p.m.–3:00 p.m.
Break
Location: Octavius Foyer
3:00 p.m.–4:30 p.m.
C8 : Neurology Update 3: Dementia; Cerebrovascular Disease 1.5
Location: Octavius 9-11
Learning Objectives: Dementia: Participants should be able to identify emerging trends in dementia prevention, navigate biomarkers for diagnostic and therapeutic strategies in Alzheimer’s disease and related disorders, and integrate emerging and approved therapies in ADRD clinical practice
Cerebrovascular Disease: Faculty will analyze new recommendations from recent literature on the management of acute ischemic stroke, outline evidence-based strategies for secondary stroke prevention based on the latest research, and review new evidence on the management of acute intracerebral hemorrhage.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» Dementia
Parichita Choudhury, MD, Sun City, AZ
3:45 p.m.–4:30 p.m.
» Cerebrovascular Disease
Victor J. Del Brutto, MD, Miami, FL
3:00 p.m.–4:30 p.m.
C9 : Controversies in Neurology 1.5
Location: Octavius 19-21
Learning Objectives: Experts will discuss the most current and controversial issues in neurology using a debate format in which two speakers argue a side of a single topic, followed by a rebuttal.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» AI Powered Automated EEG: Supervision Needed?
Edilberto Amorim, MD, San Francisco, CA
Cecil D. Hahn, MD, Toronto, ON, Canada
3:45 p.m.–4:30 p.m.
» Is a Picture Worth a Thousand Treatments: Treating the Silent Vascular Lesion?
Eric E. Smith, MD, Calgary, AB, Canada
Hugo Javier Aparicio, MD, MPH, Boston, MA
3:00 p.m.–4:30 p.m.
C10 : Practice Management 3: New Frontiers in Care: Exploring Innovative Service Lines for Community Practices 1.5
Location: Octavius 15-16
Learning Objectives: Participants should be able to recognize the importance of clinical trial access for their patients, judge if clinical trials are right for their practice, prepare their practice for clinical trial work, and develop a plan for setting in infusions.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» Exploring Innovative Service Lines for Community Practices
Amy R. Knighton, Savannah, GA
3:45 p.m.–4:30 p.m.
» Exploring Innovative Service Lines for Community Practices
Robert F. Armstrong, MD, FAAN, Asheville, NC
SCHEDULE
3:00 p.m.–4:30 p.m.
L3 : Emotional Intelligence in Action: Navigating Conflict in Difficult Times 1.5
Location: Octavius 17-18
Learning Objectives: Leadership University sessions are open to all Fall Conference attendees and are designed to be inclusive of advanced practice providers, business administrators, trainees, and neurologists at all career stages. Participants should be able to recognize the difference between conflict management and conflict de-escalation; define emotional intelligence (EI) and the key skills that support it; gain insight and strategies for how to effectively regulate their own EI skills while fostering regulation in others, especially in times of conflict; and identify growth opportunities and action steps to further develop their EI regulation when leading both self and others. Leadership development is personal development, so please join us!
Lecture/Faculty:
3:00 p.m.–4:30 p.m.
» Emotional Intelligence in Action: Navigating Conflict in Difficult Times
Anthony Izzo, DO, FAAN, Worcester, MA
Carrie M. Hersh, DO, MSc, FAAN, Las Vegas, NV
Robin Stubblefield, MA, ACC, Bloomington, MN
4:00 p.m.–5:30 p.m.
Exhibit Hall Reception
Location: Exhibit Hall - Octavius 12
7:00 a.m.–7:50 a.m.
Industry Therapeutic Update from Biogen: SKYCLARYS® (omaveloxolone)
The First and Only FDA-Approved Prescription Treatment for Friedreich Ataxia in Adults and Adolescents Aged 16 Years and Older
Location: Octavius 4
Learning Objectives: This presentation will include an introduction into the clinical background of Friedreich Ataxia (FA), a summary of the clinical efficacy and safety data from the clinical trials that studied SKYCLARYS in the treatment of FA, and the clinical management of treatment with SKYCLARYS. This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
8:00 a.m.–9:30 a.m.
C11: Neurology Update 4: Movement Disorders; Autonomic Disorders 1.5
Location: Octavius 9-11
Learning Objectives: Movement Disorders: Participants should become familiar with and be able to apply current best practice in the diagnosis and treatment of Parkinson’s disease, atypical Parkinsonian syndromes, dystonia, essential tremor, ataxia, and chorea, and receive an update on major new breakthroughs in these conditions, including medical and surgical treatments.
Autonomic Disorders: Faculty will describe recent studies that may help counselling and treating patients with chronic autonomic failure; review updates in Postural Tachycardia Syndrome (POTS) and other disorders of orthostatic intolerance, including long-COVID syndrome; and discuss how recent discoveries in basic autonomic science may translate into more effective treatments for people with autonomic disorders.
Lecture/Faculty:
8:00 a.m.–8:45 a.m.
» Movement Disorders
Pavan Vaswani, MD, Philadelphia, PA 8:45 a.m.–9:30 a.m.
» Updates in Autonomic Disorders
Guillaume Lamotte, MD, Salt Lake City, UT
SCHEDULE SATURDAY, OCTOBER 26
8:00 a.m.–9:30 a.m.
C12 : Neuromyelitis Optica Spectrum Disorders 1.5
Location: Octavius 19-21
This program is supported in part by an educational grant from UCB, Inc.
Learning Objectives: Participants should be able to elaborate the evolution of diagnostic criteria for NMOSD, describe current and future diagnostic assays for aquaporin-4 autoantibodies (AQP4-IgG), understand the clinical implications of AQP4-IgG seroreversion and seroconversion, formulate acute and preventative approaches for the care of NMOSD patients, and critically assess the potential role of biomarkers in the diagnosis and management on NMOSD.
Lecture/Faculty:
8:00 a.m.–8:25 a.m.
» AQP4-IgG: The Impact and Evolution of Serodiagnosis
Amy Kunchok, MBBS, Cleveland, OH
8:25 a.m.–8:50 a.m.
» NMOSD: Acute and Preventative Treatments in the Era of Registered Therapies
Bruce A. Cree, MD, PhD, MCR, FAAN, San Francisco, CA
8:50 a.m.–9:15 a.m.
» Biomarkers in NMOSD: Can We Measure Treatment Response?
Jeffrey L. Bennett, MD, PhD, FAAN, Aurora, CO
9:15 a.m.–10:15 a.m.
» Faculty-Audience Discussion
Jeffrey L. Bennett, MD, PhD, FAAN, Aurora, CO
Amy Kunchok, MBBS, Cleveland, OH
Bruce A. Cree, MD, PhD, MCR, FAAN, San Francisco, CA
8:00 a.m.–9:30 a.m.
C13 : Practice Management 4: From Payers to Partners: Strategies to Reduce Burden and Build Collaboration
Location: Octavius 15-16
Learning Objectives: Participants should be able to identify key negotiating partners within payer organizations; develop truly productive, collaborative relationships with payer partners; and improve administrative burden with successful negotiation.
Lecture/Faculty:
8:00 a.m.–8:45 a.m.
» From Payers to Partners: Strategies to Reduce Burden and Build Collaboration
Kavita Nair, PhD, FAAN, Aurora, CO
8:45 a.m.–9:30 a.m.
» From Payers to Partners: Strategies to Reduce Burden and Build Collaboration
Christine Mann, MBA, Amherst, NY
9:30 a.m.–10:00 a.m.
Exhibit Hall Break
Location: Exhibit Hall - Octavius 12
10:00 a.m.–11:30 a.m.
C14 : Neurological Debate: Should Patients with a Single Unprovoked
Seizure
be Evaluated and Treated as If They Have Epilepsy?
Location: Octavius 9-11
Learning Objectives: By the end of this program, participants should be able to identify the clinical criteria for diagnosing epilepsy in patients with a single unprovoked seizure; evaluate the risks and benefits of treating patients with a single unprovoked seizure as if they have epilepsy; discuss the latest evidence and guidelines regarding the management of patients with a single unprovoked seizure; and formulate individualized treatment plans for patients presenting with a single unprovoked seizure, considering patient-specific factors and preferences.
Lecture/Faculty:
10:00 a.m.–10:45 a.m.
» Should Patients with a Single Unprovoked Seizure be Evaluated and Treated as If They Have Epilepsy? (yes)
Gregory D. Cascino, MD, FAAN, Rochester, MN 10:45 a.m.–11:30 a.m.
» Should Patients with a Single Unprovoked Seizure be Evaluated and Treated as If They Have Epilepsy? (no)
Anteneh M. Feyissa, MD, MSc, FAAN, Jacksonville, FL
10:00 a.m.–11:30 a.m.
C15 : Chronic Inflammatory Demyelinating Polyneuropathy 1.5
Location: Octavius 19-21
This program is supported in part by an educational grant from argenx US Inc.
Learning Objectives: Participants should be able to describe the typical and atypical presentations of CIDP; understand the diagnostic evaluation of CIDP, including key electrodiagnostic features, and other supportive diagnostic studies; be able to identify CIDP mimics and diagnostic pitfalls; and understand both the current therapeutic approach to CIDP as well as the evolving treatment landscape.
Lecture/Faculty:
10:00 a.m.–10:40 a.m.
» The Clinical Presentation and Diagnosis of CIDP
Kelly G. Gwathmey, MD, Henrico, VA 10:40 a.m.–11:20 a.m.
» The Therapeutic Approach to CIDP
Christyn M. Edmundson, MD, Seattle, WA 11:20 a.m.–11:30 a.m.
» Questions and Answers
Kelly G. Gwathmey, MD, Henrico, VA
Christyn M. Edmundson, MD, Seattle, WA
10:00 a.m.–11:30 a.m.
C16 : Practice Management 5: Don’t Leave Money on the Table: Optimize Inpatient Coding with Refresher and Novel Codes 1.5
Location: Octavius 15-16
Learning Objectives: Particpants should recall foundational and high-frequency E/M codes for neurology practice, be able to explain the changes to inpatient E/M codes to hospital colleagues, and choose appropriate novel codes for work outside the core encounter.
Lecture/Faculty:
10:00 a.m.–11:30 a.m.
» Optimize Inpatient Coding with Refresher and Novel Codes
Frederic N. Nguyen, MD, FAAN, Richardson, TX
Pearce Korb, MD, FAAN, Richmond, VA
SCHEDULE SATURDAY, OCTOBER 26
11:30 a.m.–1:00 p.m.
Exhibit Hall Lunch
Location: Exhibit Hall - Octavius 12
12:00 p.m.–12:45 p.m.
BA Networking Session
Location: Octavius 15-16
12:00 p.m.–1:00 p.m.
Industry Therapeutic Update from Eli Lilly: Explore a New Therapy for Early Symptomatic Alzheimer’s Disease
Location: Octavius 2-3
Learning Objectives: Listen to a live presentation about the recent efficacy and safety findings of a treatment option for patients with early symptomatic Alzheimer’s disease.
This program is sponsored by, and presented on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 Fall Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
1:00 p.m.–2:30 p.m.
C17: Neurology Update 5: Neuroimmunology and Infectious Disease; Neurohospitalist
Location: Octavius 9-11
1.5
Learning Objectives: Participants should be able to describe updates in diagnostic criteria for major neuroimmunologic disorders (MOGAD, MS, autoimmune encephalitis), understand their application to clinical practice, and be aware of potential pitfalls in diagnosis; discuss new treatment options for NMOSD and MS and current methods of treatment for MOGAD and autoimmune encephalitis; be aware of the clinical trails available to the MOGAD and autoimmune encephalitis communities; utilize a new scoring system to differentiate viral from autoimmune encephalitis; and define the clinical utility of metagenomic next generation sequencing.
Lecture/Faculty:
1:00 p.m.–1:45 p.m.
» Neuroimmunology and Infectious Disease
Spencer Hutto, MD, Atlanta, GA
1:45 p.m.–2:30 p.m.
» Neurohospitalist
Mark Milstein, MD, FAAN, Bronx, NY
1:00 p.m.–2:30 p.m.
C18 : Neurology Education: Teaching on the Go: Effective Strategies for Busy Neurology Providers
Location: Octavius 19-21
Learning Objectives: This course is designed for neurologists and neurology APPs who seek to enhance their teaching effectiveness in a busy clinical environment. Participants will learn about just-in-time, goal-focused teaching strategies, engage in collaborative problem-solving, and develop practical solutions to implement in their practice immediately.
Lecture/Faculty:
1:00 p.m.–1:20 p.m.
» Introduction and Story Setting
Roy E. Strowd III, MD, FAAN, Winston Salem, NC
Tracey A. Milligan, MD, FAAN, Amawalk, NY
1:20 p.m.–1:50 p.m.
» Small Group Work
1:50 p.m.–2:10 p.m.
» Large Group Debrief
2:10 p.m.–2:30 p.m.
» Practical Application
Roy E. Strowd III, MD, FAAN, Winston Salem, NC
Tracey A. Milligan, MD, FAAN, Amawalk, NY
1:00 p.m.–2:30 p.m.
C19 : Practice Management 6: Beyond the Bedside: Bite-sized Strategies for Value-based Care Success 1.5
Location: Octavius 15-16
Learning Objectives: Partipicants should better understand the need for value-based care and culture in neurology, select the most appropriate value-based goals and metrics for their practice, choose specific tools to facilitate data collection and analysis, and compare real-world examples on VBC in neurology practices.
Lecture/Faculty:
1:00 p.m.–1:45 p.m.
» Beyond the Bedside: Bite-sized Strategies for Value-based Care Success
Lidia Maria V. Moura, MD, PhD, MPH, FAAN, Boston, MA
1:45 p.m.–2:30 p.m.
» Beyond the Bedside: Bite-sized Strategies for Value-based Care Success
Kate Sciore, Stoughton, MA
SCHEDULE SATURDAY, OCTOBER 26
1:00 p.m.–4:30 p.m.
C20 : Skills Workshop: Neurological Examination Skills for Advanced Practice Providers 3.5
Location: Octavius 17-18
Learning Objectives: Participants of this interactive workshop should gain a better understanding of the purpose of basic and advanced neurological exam skills and what neurological function they test; gain handson practice applying focused neurological exam techniques to evaluate specific common presenting neurological complaints (e.g., headache, confusion, dizziness, weakness/ paresthesias, gait abnormalities); and receive realtime feedback and correction of neurological exam technique to build focused neurological exam skills. Separate registration required.
Lecture/Faculty:
1:00 p.m.–1:15 p.m.
» Introduction
Galina Gheihman, MD, Boston, MA
1:15 p.m.–1:45 p.m.
» Rotation 1: Rotate Among 6 Stations (e.g. Sensory Changes)
Michael Bowley, MD, Boston, MA
1:45 p.m.–2:15 p.m.
» Rotation 2: Rotate Among 6 Stations (e.g. Weakness)
Margaret Naclerio, PA, Boston, MA
2:15 p.m.–2:45 p.m.
» Rotation 3: Rotate Among 6 Stations (e.g. Headache)
Galina Gheihman, MD, Boston, MA
2:45 p.m.–3:15 p.m.
» Rotation 4: Rotate Among 6 Stations (e.g. Dizziness)
Manali S. Sheth, MD, Boston, MA
3:15 p.m.–3:45 p.m.
» Rotation 5: Rotate Among 6 Stations (e.g. Altered Mental Status)
Ariel Nowicki, Dedham, MA
3:45 p.m.–4:15 p.m.
» Rotation 6: Rotate Among 6 Stations (e.g. Gait)
Shannon Anderson, PA, Portland, OR
4:15 p.m.–4:30 p.m.
» Wrap Up and Final Q&A
Galina Gheihman, MD, Boston, MA
2:30 p.m.–3:00 p.m.
Break
Location: Octavius Foyer
3:00 p.m.–4:30 p.m.
C21: Neurology Update 6: Neurology in Vulnerable Populations; Functional Neurology 1.5
Location: Octavius 9-11
Learning Objectives: Neurology in Vulnerable Populations: Participants should be able to define social determinants of health and commonly used frameworks to understand the role of social determinants of health in neurological health; describe examples of how social determinants of health lead to neurological disparities; and identify potential solutions to address the impact of social determinants of health on neurological disparities. Functional Neurological Disorder: Participants should review rule-in signs for FND diagnosis; develop a differential diagnosis for functional neurological disorder; describe diagnostic pitfalls to be aware of when considering a diagnosis of functional neurological disorder; and develop a rational diagnostic workup for a patient with a potential functional neurological disorder.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» Neurology in Vulnerable Populations
Nicole Rosendale, MD, San Francisco, CA
3:45 p.m.–4:30 p.m.
» Functional Neurological Disorder
Sara A. Finkelstein, MD, Boston, MA
3:00 p.m.–4:30 p.m.
C22 : Clinical Trials Update
Location: Octavius 19-21
1.5
Learning Objectives: Three speakers will each focus on the latest developments of interest to the clinician that have occurred in a specific subspecialty topic.
Lecture/Faculty:
3:00 p.m.–3:30 p.m.
» The Current State of Long-COVID: Clinical Trials and Ethical Aspects
Avindra Nath, MD, MBBS, FAAN, Bethesda, MD
3:30 p.m.–4:00 p.m.
» Gene Transfer Therapy: Is it Safe?
Julie A. Parsons, MD, Aurora, CO
4:00 p.m.–4:30 p.m.
» Migraine Management in Special Populations
Eric Kaiser, MD, PhD, Philadelphia, PA
3:00 p.m.–4:30 p.m.
C23 : Practice Management 7: AI on Monday Mornings: Practical Applications for Busy MDs & BAs 1.5
Location: Octavius 15-16
Learning Objectives: Participants should be able to recognize several available clinical AI tools in use by early adopters; appraise the utility of AI tools for their practice; identify potential barriers, pitfalls, and risk associated with AI usage in medical practice; and prepare their practice for piloting and use of novel clinical AI tools.
Lecture/Faculty:
3:00 p.m.–3:45 p.m.
» AI on Monday Mornings: Practical Applications for Busy MDs & BAs
Lee Williams, Amherst, NY
3:45 p.m.–4:30 p.m.
» AI on Monday Mornings: Practical Applications for Busy MDs & BAs
Lidia Maria V. Moura, MD, PhD, MPH, FAAN, Boston, MA
MISSED LEMS DIAGNOSES 1 AUTONOMIC SYMPTOMS IN MG PATIENTS MAY INDICATE
Although muscle weakness is a key characteristic of both MG and LEMS, autonomic symptoms— such as dry mouth, orthostatic hypotension, constipation, and impotence—are more common in LEMS.1
Based on a US database analysis of more than 130,000 patients1:
LEMS should be suspected in patients diagnosed with MG who have autonomic symptoms—particularly patients with suboptimal treatment responses
Vigilance for LEMS is especially warranted among patients with SCLC
At least 2% of the MG population may actually have a LEMS diagnosis and be appropriate for alternative treatments
MG, myasthenia gravis; LEMS, Lambert-Eaton myasthenic syndrome; SCLC, small cell lung cancer.
MG is the most common initial diagnosis before LEMS is diagnosed2
INITIAL DIAGNOSIS PRIOR TO CONFIRMATION OF LEMS IN A SEPARATE STUDY (N=140): MG
Muscular abnormalities
Peripheral nerve abnormalities
Intracranial/spinal cord abnormalities
Depression
Other
Early recognition of LEMS symptoms can lead to timely diagnosis and initiation of effective treatment.2
View/download the full poster presentation to learn more.
References: 1. Vernino S, Morrell D, Shechter G, Grebla R, Rosenfeld J. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) may be missed among patients with myasthenia gravis and autonomic dysfunction: results from a US database analysis. Abstract presented at: American Academy of Neurology (AAN) annual meeting. April 13-18, 2024; Denver, CO. 2. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
SCHEDULE SUNDAY, OCTOBER 27
7:30 a.m.–9:00 a.m.
C24 : Neurology Update 7: Neuromuscular Disease; Epilepsy 1.5
Location: Octavius 9-11
Learning Objectives: Participants should be familiar with recent advances in myasthenia, ALS, and Duchenne muscular dystrophy.
Lecture/Faculty:
7:30 a.m.–8:15 a.m.
» Neuromuscular Disease
Chamindra G. Laverty, MD, San Diego, CA
8:15 a.m.–9:00 a.m.
» Epilepsy
Shawniqua Williams Roberson, MD, Nashville, TN
7:30 a.m.–9:00 a.m.
C25 : Neuro-rheumatology 1.5
Location: Octavius 19-21
Learning Objectives: Participants should become familiar with the differential diagnoses and work-up, including imaging, CSF studies, CNS biopsy, of neurorheumatological diseases, and get an update on new breakthroughs in the field.
Lecture/Faculty:
7:30 a.m.–8:50 a.m.
» Case-based Discussions in Neurorheumatology
Siddharama Pawate, MD, Nashville, TN
Spencer Hutto, MD, Atlanta, GA
8:50 a.m.–9:00 a.m.
» Questions and Answers
Siddharama Pawate, MD, Nashville, TN
Spencer Hutto, MD, Atlanta, GA
9:00 a.m.–9:30 a.m.
Break
Location: Octavius Foyer
SUNDAY, OCTOBER 27
9:30 a.m.–11:00 a.m.
C26 : Neurology Update 8: Neurooncology; Neuro-ophthalmology 1.5
Location: Octavius 9-11
Learning Objectives: Neuro-oncology: Participants should be able to describe standard of care for primary tumors and new options for these neoplasms; use knowledge of emerging targeted therapies for brain metastasis to refer patients for timely clinical interventions; develop a systematic approach to undiagnosed brain masses with particular attention to possible CNS lymphoma; appreciate the problem of stroke in cancer patients and employ evidence-based treatment strategies; and diagnose and manage the neurological complications of immune checkpoint inhibitor and CAR T cell therapies.
Neuro-ophthalmology: Participants should be able to identify important details from videotaped patient histories and examinations to make uncommon but important neuro-ophthalmological diagnoses; gain knowledge about the historical description and current neuroscientific understanding of these neuro-ophthalmologic conditions; and appreciate how accurate diagnosis guides specific evidence-based therapeutic interventions.
Lecture/Faculty:
9:30 a.m.–10:15 a.m.
» Neuro-oncology
Amy A. Pruitt, MD, FAAN, Philadelphia, PA 10:15 a.m.–11:00 a.m.
» Neuro-ophthalmology
Sashank Prasad, MD, Philadelphia, PA
9:30 a.m.–11:00 a.m.
C27: Trigeminal Neuralgia: Mimics, Pharmacotherapy, and Surgical/ Interventional Treatment 1.5
Location: Octavius 19-21
Learning Objectives: Participants should gain an understanding of the pathophysiology of trigeminal neuralgia and potential neuroanatomical contributions; diagnostic features of trigeminal neuralgia; first- and second-line pharmacologic treatment options for trigeminal neuralgia; therapeutic options for treating breakthrough attacks; the characteristics of odontogenic pain; the differences between TMD and odontogenic pain with trigeminal neuralgia; the role of dentistry and the orofacial pain specialist in a multidisciplinary care model for trigeminal neuralgia; optimal interventional techniques used for the treatment of refractory trigeminal neuralgia; and optimal surgical techniques used for the treatment of trigeminal neuralgia.
Lecture/Faculty:
9:30 a.m.–9:55 a.m.
» Pathophysiology, Diagnosis, Pharmacological Management of Trigeminal Neuralgia
Shamin Masrour, MD, Dallas, TX
9:55 a.m.–10:20 a.m.
» Trigeminal Neuralgia Mimics: Headache and Orofacial Pain Differential Diagnosis and Management
Marcela Romero-Reyes, DDS, PhD, Baltimore, MD
10:20 a.m.–10:45 a.m.
» Interventional/Surgical Management of Trigeminal Neuralgia
Paul G. Mathew, MD, FAHS, FAAN, Foxboro, MA
10:45 a.m.–11:00 a.m.
» Questions and Answers
Paul G. Mathew, MD, FAHS, FAAN, Foxboro, MA
Shamin Masrour, MD, Dallas, TX
Marcela Romero-Reyes, DDS, PhD, Baltimore, MD
EXHIBIT HALL MAP
EXHIBITORS
AbbVie
Booth 31
abbvie.com
AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.
Alexion, AstraZeneca Rare Disease
Booth 48 alexion.com
Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
argenx
Booth 30
argenx.com
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.
argenx
Booth 44
argenx.com
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.
Autonomy Health
Booth 12
autonomyhealth.io
Autonomy Health is a neurology-focused MSO. We partner with independent practices to help increase revenue, decrease time on admin, and deliver a better patient experience. We accomplish this by offering a mix of technology and services to streamline the front office (scheduling, referrals and benefits verification), automate the back office (prior authorizations, billing), and integrate care delivery (bring ancillary offerings such as specialty pharmacy and infusions in-house). Our goal is to reverse consolidation in healthcare because we believe that when physicians have more autonomy, they can deliver better patient care.
Baylor Scott & White Healthcare
Booth 26
bswhealth.com
Baylor Scott & White Health is transforming healthcare for the Better, so that our patients and health plan members receive the high-value care they deserve when and where they need it. Our team of over 47,000 employees across more than 1,000 access points is committed to the well-being of every individual, family and community we serve. Through innovation, education and care delivery, we strive to provide an exceptional customer experience, while working to make healthcare more convenient and more affordable.
Biogen
Booth 22
Biogen.com
One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen discovers, develops, and delivers therapies for people living with serious neurological and neurodegenerative diseases. To learn more about Biogen please visit www.biogen.com
Brigade Health / Senior Doc Management
Booth 52
seniordoc.com
Senior Doc is a dedicated team of primary physicians, nurse practitioners, and physician assistants who provide comprehensive care for seniors in the comfort of their own homes.
Burghart Sniffin Sticks and Taste Strips
Booth 7
odofin.us
Sniffin Sticks and Taste Strips along with the SCENTinel card are used for olfactory and gustatory assessment. These tools assist the provider in assessing olfactory and gustatory function
Cartesian Therapeutics
Booth 17
cartesiantherapeutics.com www.cartesiantherapeutics.com
Catalyst Pharmaceuticals
Booth 19
catalystpharma.com
Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.
Consolidated Neuro Supply
Booth 11
neurosupply.com
Located in the heart of the technology district in Milford, OH, Consolidated Neuro Supply, Inc. is a leading provider of healthcare products used to diagnose neurological disorders and monitor critical neurological structures during high-risk surgical procedures. Product offerings include EMG needle electrodes, subdermal needle electrodes, pedicle screw and direct nerve stimulators, and disposable EEG electrodes.
Convenant HealthCare
Booth 41
covenanthealthcare.com
Covenant HealthCare is the one system in the Great Lakes Bay Region that delivers extraordinary care across generations and across specialties. We are the largest, most comprehensive health care provider in the region. We offer a broad spectrum of programs and services including a Level II Adult and Pediatric Trauma Center. It’s our compassionate and caring team that makes the difference. By working together for a healthier community, we can build a better tomorrow for generations to come.
EXHIBITORS
Craniometrix
Booth 50 craniometrix.com
Have dementia patients? Get them better support, improve outcomes, and create new revenue. Leveraging the Medicare GUIDE model, Craniometrix provides wraparound care support to dementia patients and families. You maintain clinical ownership and can generate thousands per patient per year -- without any new work.
Our AI tools and highly-trained care navigators, created in collaboration with the Johns Hopkins MIND at Home program, support patients and families 24/7. Learn how at craniometrix.com!
Creyos Health
Booth 36
cambridgebrainsciences.com
Cambridge Brain Sciences is a leading platform for the assessment of cognition function, used widely by mental health, brain injury and general wellness professionals to obtain quantified and scientifically-validated measures of cognitive function in areas that are key to quality of life.
Eli Lilly and Company
Booth 20 lilly.com
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.
Endeavor Health
Booth 2
eehealth.org
Endeavor Health is nine-hospital system with a broad footprint in the Chicagoland area. Our group provides coverage at two hospitals in the western suburbs. A fully integrated, healthcare delivery system with nine (9) hospitals and more than 2,400 affiliated physicians, including 975 members of the NorthShore University Medical Group with more than 140 practice locations. Our Neurosciences programs include a comprehensive stroke center with neurointerventional/endovascular services, a dedicated cardiac and neurocritical care units staffed by neurointensivists, and robust neuro-oncology and multidisciplinary neurology programs
Genentech
Booth 24
gene.com
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com. Products: Ocrevus, Enspryng, Lytics & Evrysdi.
Image Monitoring USA
Booth 45
imagemonitoringusa.com
Image Monitoring USA provides Innovative Ergonomic TCD and Physiologic Peripheral Vascular Diagnostic Testing Systems to clinics and hospitals across the USA. With our experienced Vascular Consultants, we can support and service your diagnostic vascular testing needs. We offer several ways to increase your facilities diagnostic testing capabilities and revenue.
IntraBio
Booth 47
intrabio.com
IntraBio is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurodegenerative diseases with high unmet medical needs
IntuiTap Medical, Inc.
Booth 8
intuitapmedical.com
IntuiTap Medical is a medical device start-up eliminating the guesswork, frustration, and pain from neuraxial procedures, including lumbar punctures (LPs) and epidurals. Their novel, FDAapproved device, VerTouch, uses tactile imaging to present an intuitive image of the lumbar region and assist in identification and marking of a needle insertion site. By improving procedure performance at the bedside, VerTouch helps reduce the need to refer challenging LP cases to radiology or rely on limited alternatives.
IPSEN Biopharmaceuticals Inc.
Booth 40
ipsenus.com
Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we develop and commercialize medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Disease. We work to provide hope for patients whose lives are challenged by difficult-to-treat diseases, including neurological disorders such as certain types of spasticity and cervical dystonia. Our people are driven by a passion to help patients and bring our mission to life every day. We are always ready to listen to—and learn from—patients. Every day, our more than 5,700 employees worldwide, including over 600 in North America, work diligently to improve the lives of patients around the world. For more information please visit www.ipsenus.com
EXHIBITORS
Jaan Health
Booth 43 phamily.com
The Phamily platform enables leading neurology practices to run high-quality Chronic Care Management programs for 1000s of patients. Patients (and caregivers) build trusted relationships with their practices via two-way text messaging. With 365-day insight into health issues, practices can intervene early and keep care in an outpatient setting – while being fairly compensated for all the work staff do between visits. Learn more at Phamily.com.
Kaiser Permanente/ The Permanente Medical Groups
Booth 3
physiciancareers-ncal.kaiserpermanente.org/
Kaiser Permanente is passionate in our commitment to improving the nation’s health care system. Through our leadership in the use of advanced technology, our creation of innovative solutions and our influence on health policy and reform efforts, we are shaping the future of health care both nationally and abroad.
Lundbeck
Booth 38 lundbeck.com
Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, is tirelessly dedicated to restoring brain health, so every person can be their best. Lundbeck has a long heritage of innovation in neuroscience and is focused on delivering transformative treatments that address unmet needs in brain health. For more information, visit us at www.lundbeck.com/us
Mayo Clinic Laboratories
Booth 54
mayocliniclabs.com
Mayo Clinic Laboratories strives to ensure patients around the world have access to the most advanced diagnostic testing. Working with hospitals and healthcare providers worldwide, we deliver the latest in diagnostic testing to provide answers and improve outcomes for their patients. With the world’s most sophisticated test catalog, our testing incorporates scientific discoveries, cutting-edge technologies, and unparalleled expertise to solve the most rare and complicated cases.
McKesson
Booth 29
mckesson.com
McKesson helps neurology providers run profitable, independent businesses by clearing the path for them to focus on patient care. We offer an impactful portfolio of solutions that makes practice management more manageable by increasing efficiency, productivity, and profitability for specialty providers. Our Onmark Group Purchasing Organization (GPO) helps providers maximize their purchasing power, while our support services go above and beyond the essentials of pharmaceutical distribution. We take a highly-collaborative “all in” approach to understanding each practice’s unique needs. This tailored approach informs the business insights, strategies, and resources we offer, including regulatory guidance, advocacy, and full-service management options for physicianowned specialty practices. Intrafusion by McKesson is full-service infusion management that clears the path for independent, community-based specialty providers to care for their patients while growing a successful, high-quality infusion center. Our “all in” approach combined with proven results and a comprehensive portfolio of solutions ensure your infusion center operates productively, efficiently and profitably. Our broad portfolio of services is unparalleled, as is our commitment to supporting each provider’s ability to deliver better patient care and outcomes. That’s the McKesson difference. Ask us how we can help: mckesson.com/specialty
Medeia
Booth 21
medeia.com
www.medeia.com
Memorial Hermann Health System
Booth 27
memorialhermann.org
Charting a better future. A future that’s built upon the HEALTH of our community. This is the driving force for Memorial Hermann, redefining health care for the individuals and many diverse populations we serve. Our 6,600+ affiliated physicians and 33,000+ employees practice the highest standards of safe, evidence-based, quality care to provide a personalized and outcome-oriented experience across our more than 260 care delivery sites.
MicroTransponder Inc.
Booth 9
vivistim.com
First Ever Chronic Stroke Recovery device using “Paired Vagus Nerve Stimulation” implant called Vivistim. Vivistim received FDA Designated Breakthrough status. Vivistim is covered by many insurance companies with CMS NTAP and TPT designation.
Mirum Pharma
Booth 4
mirumpharma.com
At Mirum, we are committed to developing safe and effective therapies for people with rare diseases. Ultimately, we want to help patients and their families experience a bright future.
Neurocrine Biosciences
Booth 37 neurocrine.com
Neurocrine Biosciences, Inc. discovers and develops innovative and life‐changing pharmaceuticals utilizing our novel R&D platform. Neurocrine’s efforts are focused on conditions with high unmet medical needs, specifically in neurologic, psychiatric, and endocrine based diseases and disorders.
Neurocrine Biosciences
Booth 55 neurocrine.com
Neurocrine Biosciences, Inc. discovers and develops innovative and life‐changing pharmaceuticals utilizing our novel R&D platform. Neurocrine’s efforts are focused on conditions with high unmet medical needs, specifically in neurologic, psychiatric, and endocrine based diseases and disorders.
NeuroNet GPO
Booth 25
neuronetgpo.com
NeuroNet GPO is a group purchasing organization focused on serving the needs of outpatient clinical practices and their ancillary services. GPO members partner with practices nationwide to leverage purchase power, resulting in discounted pricing on drugs and supplies. Members also gain access to valuable information and resources, which helps maximize operating performance.
EXHIBITORS
Octapharma
Booth 42
octapharma.com
Octapharma USA, is a subsidiary for Octapharma AG, a global human protein products powerhouse dedicated to the research and manufacture of human proteins. Patients are treated with Octapharma products in the therapeutic areas of hematology, immunology, and critical care. To learn more about Octapharma USA, please visit www.octapharmausa.com
\ OI Infusion
Booth 39 oi-infusion.com
Adding or expanding infusion services can be risky and expensive on your own. But having a capable, dependable partner like OI Infusion takes that weight off your shoulders. We partner with healthcare entities across the country, managing the business and clinical aspects of your infusion suite. We’re on a mission to improve infusion care, one patient, one provider, one practice at a time.
PeaceHealth
Booth 35
peacehealth.org
PeaceHealth, based in Vancouver, Washington, is a not-for-profit Catholic health system offering care to communities in Washington, Oregon and Alaska. PeaceHealth has approximately 16,000 caregivers, a medical group practice with more than 1,200 providers and 9 medical centers serving both urban and rural communities throughout the Northwest. PeaceHealth has once again been recognized for the health and wellness of our caregivers as one of the Healthiest 100 Workplaces in America. - Healthiest Employers For the third year in a row, PeaceHealth has received top ranking as the No.1 Healthiest Employer in Washington.Springbuk Portland Business Journal has ranked PeaceHealth as the No. 1 Healthiest Employer in Oregon in 2023.
Phagenesis
Booth 5 phagenesis.com
Phagenesis is a med tech company offering innovative neurosttimulation therapies to treat stroke patients who suffer from swallowing problems.
Physicians Practice Enhancement
Booth 14 ppenet.com
Physicians’ Practice Enhancement, LLC is committed to the highest level of patient, hospital and physician satisfaction. As a physician-led organization, we recognize that our success is dependent on the professional satisfaction and success of our physicians and providers. At PPE, our family of clinical providers is the heart of our organization. PPE works with our clinical providers to identify long term professional goals and provide the necessary tools to fulfill these goals. In addition to professional development, PPE offers leadership training, especially for those seeking clinical administrative goals. We reinforce this family values and emphasis on education and training through our firm commitment to promote from within. PPE’s diverse corporate team of clinical directors, practice managers, client services, payroll, human resources, and provider enrollment offer “back-office” support, such as 24/7 scheduling services, allowing you to focus more time on patient care.
PX Technology, now part of CareMetx
Booth 53
pxtechnology.com
PX Technology is a pioneer in digitizing healthcare processes to enhance patient access to therapies. With its flagship platform, PX Connect, the company simplifies the patient enrollment process for healthcare providers, offering a seamless solution that integrates into existing workflows. PX Technology’s mission is to streamline the bridge between patients and their access to necessary treatments, focusing on efficiency, innovation, and the improvement of patient care through technology. For more information, visit their website at pxtechnology.com
\
Pyramids Infusion
Booth 10
pyramidspharmacy.com
Pyramids Infusion is a full-service infusion provider with a focus on immunoglobulin therapy and home health. In addition to home health services, Pyramids offers access to rapidly expanding infusion suites. These stateof-the-art infusion suites prioritize patients’ comfort. Pyramids’ dedicated staff of in-house nurses, pharmacists and clinicians ensure the highest quality of care. Pyramids Infusion aims to achieve market-leading turnaround times from intake to the start of therapy. A highly experienced team ensures a high approval rate and fast turnaround time for authorization/ appeal resolution. Licensed in 49 states, Pyramids Infusion aims to offer unparalleled care and convenience for patients nationwide.
RosmanSearch
Booth 1
rosmansearch.com/for/Home.html
RosmanSearch is a specialized physician recruitment firm with an edge. Our unique approach blends data-driven insights with a highly focused team of recruiters ensuring impactful placements. We don’t just fill positions; we lean on our expertise in neurosurgery, neurology, urology, gastroenterology and hospitalist medicine to curate matches that elevate healthcare standards. Whether permanent placement, executive search, or locum tenens, our experienced recruiters utilize robust data analytics and unparalleled expertise to ensure unmatched precision in every placement.
SamaCare
Booth 18
samacare.com
SamaCare is one place to submit, track and manage all prior authorizations across all payers and drugs.
Sevaro Health, Inc
Booth 16
sevaro.com
Sevaro provides telestroke, teleneurology, and EEG services to hospitals and health systems.
EXHIBITORS
SpringWorks Therapeutics
Booth 6
springworkstx.com
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. We have a diversified targeted therapy pipeline spanning solid tumors and hematological cancers. For more information, visit www.springworkstx.com and follow @SpringWorksTx on X and LinkedIn.
Sutter Health
Booth 13
jobs.sutterhealth.org
Sutter Health is one of the nation’s leading community-based, not-for-profit health care networks of hospitals, physician organizations, home health and hospice agencies and other health care services. We share our expertise and resources to advance the quality of care in the communities we serve. We offer our employees an environment that is conducive to professional performance. Our facilities and services are located in large, urban cities and small, rural communities from the Pacific Coast to the Sierra Foothills and from the Oregon border to the San Joaquin Valley. They are situated near major West Coast attractions: San Francisco, Sacramento, the snowy mountains of the Sierra Nevada and Lake Tahoe, the Napa Valley, Yosemite Valley and the coastal redwoods. We even have an affiliate in Hawaii.
SynapsDX
Booth 51 synapsdx.com
Pioneering Precision in Alzheimer’s Diagnostics
Takeda Pharmaceuticals
Booth 34
takeda.com
Takeda Neuroscience is driven by the unmet needs of patients with rare neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. To deliver on this mission, our approach leverages advances in molecularly and genetically defined targets, biomarkers, and targeted modalities. Our commitment to patients is focused on our goal of developing new treatments for those who need them most.
The American Institute of Balance
Booth 49 dizzy.com
Founded in 1992, AIB has grown into the country’s largest network of neurodiagnostic and rehabilitation balance specialists. AIB licenses, owns, or operates 100 Centers of Specialty Care clinics specializing in the evaluation and treatment of dizziness and balance disorders. Our education programs have trained and certified over 5000 physical and occupational therapists. Our research, diagnostic, and therapy protocols are used by leading practitioners, hospitals, and universities worldwide.
UCB, Inc.
Booth 15
ucb.com
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Follow us on Twitter: @UCB_news.
US
Neuro
Booth 46
usneuro.net
US Neuro is a national, private-practice group dedicated to providing the best neuro diagnostic services to all markets with the highest level of IONM and EEG Services available.
Wolters Kluwer
Booth 28
lww.com
Wolters Kluwer Health is a global provider of information, business intelligence and pointof-care solutions for the healthcare industry . Brands include Lippincott Williams & Wilkins, a leading international publisher of medical books, electronic media and journals and the official publisher of American Academy of Neurology. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit our booth to browse our comprehensive product line.
SELECT IMPORTANT SAFETY INFORMATION
Warnings & Precautions
• Alterations in Endocrine Function: Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events. Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal.
• Immunosuppression and Increased Risk of Infection: Use of corticosteroids, including AGAMREE, increases the risk of new infection, exacerbation of existing infections, dissemination, and reactivation or exacerbation of latent infection and may mask some signs of infection; these infections can be severe, and at times fatal.
• Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and monitor sodium and potassium levels in patients chronically treated with AGAMREE.
• Gastrointestinal Perforation: Use of corticosteroids increases the risk of gastrointestinal perforation in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs and symptoms may be masked.
• Behavioral and Mood Disturbances: Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE, and may include hypomanic or manic symptoms (eg, euphoria, insomnia, mood swings) during treatment and depressive episodes after discontinuation of treatment.
• Effects on Bones: Prolonged use of corticosteroids, such as AGAMREE, can lead to osteoporosis, which can predispose patients to vertebral and long bone fractures. Monitor bone mineral density in patients on long-term treatment with AGAMREE.
• Ophthalmic Effects: The use of corticosteroids, such as AGAMREE, may increase the risk of cataracts, ocular infections, and glaucoma. Monitor intraocular pressure if treatment with AGAMREE is continued for more than 6 weeks.
• Vaccination: Do not administer live-attenuated or live vaccines to patients receiving AGAMREE. Administer liveattenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE.
Please see Brief Summary of full Prescribing Information on the next page.
AGAMREE® (vamorolone) oral suspension
BRIEF SUMMARY – See Full Prescribing Information at AGAMREEhcp.com
Initial U.S. Approval: 2023
INDICATIONS AND USAGE
AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
DOSAGE AND ADMINISTRATION
Dosing Information
The recommended dosage of AGAMREE is 6 mg/kg taken orally once daily preferably with a meal, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg. Some patients may respond to a dose of 2 mg/kg daily. Doses may be titrated down to 2 mg/kg/day as needed, based on individual tolerability.
Discontinuation
Dosage of AGAMREE must be decreased gradually if the drug has been administered for more than one week.
CONTRAINDICATIONS
AGAMREE is contraindicated in patients with known hypersensitivity to vamorolone or to any of the inactive ingredients of AGAMREE. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy.
WARNINGS AND PRECAUTIONS
Alterations in Endocrine Function
Corticosteroids, such as AGAMREE, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal.
In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events.
Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal. The risk of adrenal insufficiency is reduced by gradually tapering the dose when withdrawing treatment. For patients already taking corticosteroids during times of stress, the dosage may need to be increased.
Immunosuppression and Increased Risk of Infection
Corticosteroids, including AGAMREE, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens.
Corticosteroids can reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections, increase the risk of reactivation or exacerbation of latent infections, and mask some signs of infection.
Corticosteroid-associated infections can be mild but can be severe, and at times fatal.
The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider AGAMREE withdrawal or dosage reduction as needed.
Tuberculosis
If AGAMREE is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged AGAMREE therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.
Varicella Zoster and Measles Viral Infections
Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including AGAMREE. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles.
• If an AGAMREE-treated patient is exposed to varicella, prophylaxis with varicella zoster immunoglobulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
• If an AGAMREE-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.
Hepatitis B Virus Reactivation
Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including AGAMREE Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.
Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with AGAMREE. For patients who show
evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections
Corticosteroids, including AGAMREE, may exacerbate systemic fungal infections; therefore, avoid AGAMREE use in the presence of such infections unless AGAMREE is needed to control drug reactions. For patients on chronic AGAMREE therapy who develop systemic fungal infections, AGAMREE withdrawal or dosage reduction is recommended.
Amebiasis
Corticosteroids, including AGAMREE, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating AGAMREE in any patients who have spent time in the tropics or patients with unexplained diarrhea.
Strongyloides Infestation
Corticosteroids, including AGAMREE, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Cerebral Malaria
Avoid corticosteroids, including AGAMREE, in patients with cerebral malaria.
Alterations in Cardiovascular/Renal Function
Corticosteroids, including AGAMREE, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium.
Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels.
AGAMREE should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Literature reports suggest an association between use of corticosteroids and left free wall rupture after a recent myocardial infarction; therefore, therapy with AGAMREE should be used with great caution in these patients.
Gastrointestinal Perforation
There is an increased risk of gastrointestinal perforation with the use of corticosteroids in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids.
Avoid AGAMREE if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; or active or latent peptic ulcer.
Behavioral and Mood Disturbances
Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE. Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. These reactions may improve after either dose reduction or withdrawal, although pharmacologic treatment may be necessary.
Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected.
Effects on Bones
Decreased Bone Mineral Density
Corticosteroids, such as AGAMREE, decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of bone loss at any age. Bone loss can predispose patients to vertebral and long bone fractures.
Consider a patient’s risk of osteoporosis before initiating corticosteroid therapy. Monitor bone mineral density in patients on long-term treatment with AGAMREE.
Avascular Necrosis
Corticosteroids may cause avascular necrosis.
Ophthalmic Effects
The use of corticosteroids, such as AGAMREE, may produce posterior subcapsular cataracts.
Corticosteroids may also cause glaucoma with possible damage to the optic nerves, and may increase the risk of secondary ocular infections caused by bacteria, fungi, or viruses. Corticosteroids are not recommended for patients with active ocular herpes simplex. Intraocular pressure may become elevated in some patients taking corticosteroids. If treatment with AGAMREE
is continued for more than 6 weeks, monitor intraocular pressure.
Immunizations
Administer all immunizations according to immunization guidelines prior to starting AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE. Patients on AGAMREE may receive concurrent vaccinations, except for live-attenuated or live vaccines.
Effects on Growth and Development
Long-term use of corticosteroids, including AGAMREE, can have negative effects on growth and development in children.
Myopathy
Patients receiving corticosteroids and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.
Kaposi’s Sarcoma
Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.
Thromboembolic Events
Observational studies have shown an increased risk of thromboembolism (including venous thromboembolism) particularly with higher cumulative doses of corticosteroids. It is unclear if risk differs by daily dose or duration of use. Use AGAMREE with caution in patients who have or may be predisposed to thromboembolic disorders.
Anaphylaxis
Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy.
ADVERSE REACTIONS
The following serious adverse reactions are discussed in more detail in other sections:
• Alterations in Endocrine Function
• Immunosuppression and Increased Risk of Infection
• Alterations in Cardiovascular/Renal Function
• Gastrointestinal Perforation
• Behavioral and Mood Disturbances
• Effects on Bones
• Ophthalmic Effects
• Immunizations
• Effects on Growth and Development
• Myopathy
• Kaposi’s Sarcoma
• Thromboembolic Events
• Anaphylaxis
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Common Adverse Reactions in Clinical Studies
Table 1 lists the adverse reactions that occurred in ≥5% of the patients treated with AGAMREE 6 mg/ kg/day (N=28) or AGAMREE 2 mg/kg/day (N=30) and that occurred more frequently than in the patients who received placebo (N=29) in Study 1, which was 24 weeks and included patients with DMD between the ages of 4 and 7 years.
Table 1: Adverse Reactions in Patients with DMD that Occurred in ≥5% of Patients Treated with AGAMREE and More Frequently than in Patients Who Received Placebo During 24 Weeks (Study 1)
are required when AGAMREE is concomitantly administered with moderate or weak CYP3A4 inhibitors.
USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary
AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, corticosteroids in general should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. There are no data on the use of AGAMREE during pregnancy.
Animal reproduction studies have not been conducted with AGAMREE.
Lactation
Risk Summary
There are no data on the presence of vamorolone in human milk or the effects on milk production. AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need and any potential adverse effects on the breastfed infant.
Pediatric Use
The safety and effectiveness of AGAMREE for the treatment of DMD have been established in patients 2 years of age and older. Use of AGAMREE in pediatric patients is supported by a multicenter, randomized, double-blind, placebo- and activecontrolled study in 121 males 4 to less than 7 years of age. Use of AGAMREE in patients 2 years to less than 4 years of age and 7 to less than 18 years of age is supported by findings of efficacy and safety in patients 4 to less than 7 years of age with DMD, and by pharmacokinetic and safety data from patients 2 to 4 years of age and 7 to less than 18 years of age.
The safety and effectiveness in pediatric patients below the age of 2 years have not been established.
Geriatric Use
DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with AGAMREE.
Hepatic Impairment
Moderate hepatic impairment increases vamorolone exposure. Reduce the AGAMREE dosage in patients with mild to moderate hepatic impairment. There is no clinical experience with AGAMREE in patients with severe hepatic impairment, and a dosing recommendation cannot be provided for patients with severe hepatic impairment.
CLINICAL PHARMACOLOGY
Mechanism of Action
Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert antiinflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.
Pharmacodynamics
Vamorolone produced a dose-dependent decrease in morning cortisol levels in the clinical studies. Treatment with corticosteroids is associated with a suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. A dose-dependent increase in leukocyte counts and lymphocyte counts was observed in clinical studies with vamorolone.
Cardiac Electrophysiology
Vamorolone does not cause a mean increase in the QTc interval >20 milliseconds (ms) at 1.6 times the approved recommended dose.
See full Prescribing Information available at AGAMREEhcp.com.
1Includes the following adverse reactions that occurred more frequently in the AGAMREE group than in placebo: abnormal behavior, aggression, agitation, anxiety, irritability, mood altered, sleep disorder, and stereotypy.
In a separate open-label safety study of pediatric patients aged 2 to less than 4 years (n=16) and pediatric patients aged 7 to less than 18 years (n=16) with DMD, adverse reactions were similar to those seen in the Study 1 pediatric patients.
DRUG INTERACTIONS
Effect of Other Drugs on Vamorolone
Co-administration of AGAMREE with itraconazole, a strong CYP3A4 inhibitor, increases vamorolone exposure. Reduce the dosage of AGAMREE in patients when strong CYP3A4 inhibitors are used concomitantly. No dosage adjustments
